INBX
Inhibrx Biosciences, Inc. NASDAQ Listed Jun 4, 2024$141.84
Pre-mkt
$141.20
-0.45%
Mkt Cap $2.1B
52w Low $10.84
90.7% of range
52w High $155.29
50d MA $82.67
200d MA $62.58
P/E (TTM)
-14.2x
EV/EBITDA
-9.1x
P/B
249.5x
Debt/Equity
13.4x
ROE
-1752.2%
P/FCF
-9.4x
RSI (14)
—
ATR (14)
—
Beta
1.83
50d MA
$82.67
200d MA
$62.58
Avg Volume
284.0K
About
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-1…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -2.08 | -2.11 | -1.4% | 64.87 | -1.5% | -6.1% | -0.4% | -2.7% | +2.5% | +1.4% | — |
| Nov 14, 2025 | AMC | -2.08 | -2.28 | -9.6% | 79.13 | +0.0% | -2.2% | -1.9% | +3.8% | +0.9% | +6.1% | — |
| Aug 13, 2025 | AMC | -2.92 | -1.85 | +36.6% | 23.57 | +2.0% | +1.6% | -1.0% | +1.3% | -2.4% | +3.6% | — |
| May 14, 2025 | AMC | -2.55 | -2.80 | -9.8% | 10.84 | +1.2% | +10.9% | +13.7% | +15.0% | +20.6% | +21.4% | — |
| Mar 17, 2025 | AMC | -2.88 | -3.09 | -7.3% | 13.94 | -2.9% | +0.4% | +0.4% | +1.1% | +2.9% | +5.6% | — |
| Nov 14, 2024 | AMC | -3.06 | -2.84 | +7.2% | 14.33 | +0.0% | -3.5% | -5.0% | -0.3% | -2.0% | -2.4% | — |
| Aug 13, 2024 | AMC | -3.60 | 125.48 | +3585.6% | 11.30 | -0.3% | -0.1% | +9.7% | +10.3% | +14.6% | +14.2% | — |
| Jun 3, 2024 | AMC | -1.04 | -1.44 | -38.5% | 18.02 | +2.4% | -4.5% | -6.3% | -9.9% | -7.6% | -7.9% | — |
| Feb 28, 2024 | AMC | -1.07 | -1.73 | -61.7% | 37.00 | -0.1% | -1.0% | -1.5% | -3.7% | -3.8% | -3.5% | — |
| Nov 9, 2023 | AMC | -1.01 | -1.10 | -8.9% | 18.30 | +1.0% | +4.4% | +7.6% | +10.5% | +10.8% | +14.8% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 22 | JMP Securities | Maintains | Market Perform → Market Perform | — | $24.16 | $24.45 | +1.2% | +3.5% | +3.6% | +7.3% | +13.4% | +15.4% |
| May 15 | JMP Securities | Maintains | Market Perform → Market Perform | — | $10.84 | $10.97 | +1.2% | +10.9% | +13.7% | +15.0% | +20.6% | +21.4% |
| Mar 18 | Citizens Capital Markets | Maintains | Market Perform → Market Perform | — | $13.94 | $13.53 | -2.9% | +0.4% | +0.4% | +1.1% | +2.9% | +5.6% |
| Jan 22 | JMP Securities | Maintains | Market Perform → Market Perform | — | $14.19 | $14.01 | -1.3% | -4.2% | -7.8% | -7.3% | -12.5% | -13.7% |
| Jan 23 | JMP Securities | Downgrade | Market Outperform → Market Perform | — | $33.33 | $35.50 | +6.5% | +8.9% | +8.8% | +12.5% | +12.8% | +14.0% |
| Nov 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $22.29 | $22.44 | +0.7% | -0.1% | -11.4% | -7.9% | -7.9% | -8.8% |
| Aug 23 | JMP Securities | Maintains | Outperform → Outperform | — | $19.06 | $19.09 | +0.2% | +2.0% | -1.6% | -5.0% | +1.5% | +15.1% |
| May 10 | JMP Securities | Maintains | Market Outperform → Outperform | — | $26.31 | $26.29 | -0.1% | -1.7% | -4.7% | -6.0% | -4.4% | -5.9% |
| Mar 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $23.97 | $23.88 | -0.4% | -2.6% | -5.1% | -10.5% | -4.8% | -1.6% |
| Mar 7 | Credit Suisse | Maintains | Outperform → Outperform | — | $23.69 | $22.76 | -3.9% | +1.2% | -1.5% | -4.0% | -9.5% | -3.7% |
Recent Filings
8-K · 8.01
!! High
Inhibrx Biosciences, Inc. -- 8-K 8.01: Material Event / Announcement
Inhibrx Biosciences updated its corporate presentation on April 21, 2026, indicating potential strategic communications or business developments for investors to review on its website.
Apr 21
8-K
Unknown — 8-K Filing
Inhibrx released FY2025 results, signaling operational progress that investors should evaluate against pipeline advancement, cash burn rate, and path to revenue generation for biotech valuation.
Mar 19
8-K · 7.01
! Medium
Inhibrx Biosciences, Inc. -- 8-K 7.01: Regulation FD Disclosure
Inhibrx Biosciences disclosed a presentation to investors detailing company updates and business summaries, typically delivered at conferences and investor meetings.
Feb 23
Data updated apr 25, 2026 3:29pm
· Source: massive.com